---
title: "Policy Pulse — Trump/US — 31 Jul 2026"
ticker: "LLY:MRK:JNJ:PFE:ABBV:F:GM:TAP:STZ:SPY:QQQ"
date: "2026-07-31"
tags: ["policy-pulse","us-only","pharma","tariffs"]
summary: "US Pharmaceutical Section 232 tariffs take effect today: 100% on branded patented drugs, generics exempt. Structural BUY for LLY, MRK, JNJ, PFE, ABBV. Watch Sept 29 expansion."
model: "deepseek-chat"
---

# Policy Pulse — Trump/US — 31 Jul 2026

## 💊 Section 232 Pharmaceutical Tariffs Take Effect Today — Branded Drugs at 100%, Generics Exempt

The **July 31, 2026** deadline hit today for Trump's Pharmaceutical Section 232 tariffs, imposed under the Trade Expansion Act of 1962. The tariffs apply additional duties of up to **100% on patented brand-name pharmaceuticals and their active ingredients (APIs)** imported into the United States.

**The key nuance — this is NOT a blanket pharma tariff:**

- **17 named companies (Annex III)** — mostly the large global branded drugmakers — face the 100% duty from **today (Jul 31)**. However, most of these have secured tariff exemptions via "MFN pricing agreements" or the **20% onshoring incentive** — companies that commit to shifting production to the US can reduce the rate to 20%.
- **Generics and biosimilars are EXPRESSLY EXCLUDED** from the Section 232 duties — both in the proclamation and via the India-US negotiated deal that favors generic drugmakers.
- **EU, Japan, Korea** face a tiered **15%** rate; **UK** at 10%.
- A second, broader deadline for **all other importers arrives Sept 29, 2026**.

### Stocks to Watch

| Stock | Impact | Reason |
|-------|--------|--------|
| LLY | 🟢 Positive | Branded pharma — protected from import competition, MFN/onshoring deal softens rate |
| MRK | 🟢 Positive | Branded drug leader — direct beneficiary of tariff wall against foreign generics |
| JNJ | 🟢 Positive | Diversified branded pharma — competitive protection is structural positive |
| PFE | 🟢 Positive | Innovator pharma — high-price branded drugs insulated |
| ABBV | 🟢 Positive | Branded specialty pharma — Humira etc. protected from low-cost entrants |
| UNH | 🟡 Hold | Managed care/healthcare — broader healthcare pricing backdrop mixed |
| GILD | 🟡 Hold | Branded but specialty — limited direct exposure, watch Sept 29 list |

**Key insight:** The Section 232 pharma tariff is structurally **protective for US branded/innovator pharma (LLY, MRK, JNJ, PFE, ABBV)** — it erects a 100% wall against foreign patented drugs while exempting generics. The "20% onshoring incentive" rewards US manufacturing, a positive for durability of US pharma earnings. The wildcard is the **Sept 29** expansion to all importers.

---

## 🇨🇦 Canada 50% Section 338 Tariffs — Approaching Effective Date (Mid-Aug)

Trump's **Section 338 tariffs** on Canadian autos, alcohol, and dairy ($20B, 50%) — invoked under the 1930 Tariff Act, first use in ~100 years — approach their effective date (30 days from the Jul 20 signing = **mid-Aug 2026**). No new action today, but the countdown continues.

| Stock | Impact | Reason |
|-------|--------|--------|
| F | 🟡 Hold | US auto exposure to Canadian supply chains — watch mid-Aug trigger |
| GM | 🟡 Hold | Same — cross-border auto tariff risk |
| TAP | 🔴 Negative | Alcohol import exposure — Canadian/liquor tariff hit |
| STZ | 🔴 Negative | Imported beer/wine/liquor costs rise |

---

## 📊 Fed / Macro — Crude Easing, Market Stabilizing After Yield Shock

After the Jul 29 Fed hawkish hold sent 30-yr yields to 2007 highs, markets are stabilizing. Crude has eased off the Hormuz spike, supporting a modest risk-on tone into week's end. Indian finance ministry and RBI monitor the USD/INR (rupee at a 3-week high ~95.4/$).

| Stock | Impact | Reason |
|-------|--------|--------|
| SPY | 🟡 Hold | Stabilizing after yield spike — watch Sept FOMC |
| QQQ | 🟡 Hold | Tech steady as crude eases, but yields still elevated |
| XOM | 🟡 Hold | Crude easing off highs — oil gains partial |
| CVX | 🟡 Hold | Same — energy consolidating |

---

## Summary

Today's dominant US signal is the **Pharma Section 232 tariff taking effect (Jul 31)** — a durable structural **BUY for US branded/innovator pharma (LLY, MRK, JNJ, PFE, ABBV)** and a confirmed **exemption for generics**, defusing the Jul 22 generic-tariff scare. Watch **Sept 29** for the all-importer expansion and **mid-Aug** for the Canada 50% Section 338 tariffs.

**Tickers in focus:** LLY, MRK, JNJ, PFE, ABBV